Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.46 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545351 | 0.90 | TRPV1 (0.43) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL2545349 | 0.90 | TRPV1 (0.43) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL1744182 | 0.81 | PTPN1 (0.45) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL1519845 | 0.77 | ITGB3 (0.54) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL29551169 | 0.77 | ITGB3 (0.54) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL18248113 | 0.77 | ITGB3 (0.54) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL1519675 | 0.77 | ITGB3 (0.54) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL12737973 | 0.76 | CTSS (0.53) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL5319509 | 0.76 | ACE (0.50) | ACEPPARAPPARGPTPN1CTSS | |
| SCHEMBL5321402 | 0.76 | CTSS (0.53) | ACEPPARAPPARGPTPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | ACE 2501/4885PPARA 896/4885PPARG 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.